SpePharm to acquire extravasations drug from TopoTarget

SpePharm has agreed a deal to purchase the biotech company TopoTarget’s rights to Savene, a drug which prevents extravasations of certain cancer treatments.

The pharmaceutical company will acquire the rights to sell the drug in all territories aside from the Americas and will be taking on TopoTarget’s European sales team as part of the agreement.

This treatment helps to prevent anthracycline cancer drugs from leaking out of the bloodstream and causing damage and has been approved in Europe since 2006.

Jean-Francois Labbe, managing director and chief executive officer of SpePharm, expressed confidence that sales of Savene will grow as a result of this purchase.

He added: “Savene ? will give SpePharm the opportunity to expand its commercial presence into several additional European countries and reinforce our position in hospital oncology departments throughout Europe.”

SpePharm’s portfolio of products also includes treatments such as the hyperthermia drug Dantrium and MuGard, which combats oral mucositis caused by radiotherapy and chemotherapy.